Important disclaimers (please read first)
- This is education only. Not medical advice, legal advice, a diagnosis, or a treatment plan.
- We are not saying you are a candidate. A physician decides only after a proper consult at Regen Therapy MD.
- Results vary. No outcome, result, or product-quality guarantee.
- Brand FDA-approved products are not the same as compounded versions. Not equivalent or interchangeable.
- Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing-even under 503A or 503B conditions.
- This page does not recommend shopping channels. Not a guide to buy, import, or self-source medicines.
- No dosing or protocols.
- Licensure and shipping apply only where we are licensed-not a claim of service in all 50 states.
- Free discovery call is a non-clinical chat about what you may be a candidate for.
- Claims and sources lean on cited FDA pages (plus one CRS history summary).
Why channels still matter
Patients deserve a plain-language map of licensed U.S. compounding channels-prescription for you, licensed entities, pharmacist oversight, documentation you can ask about-versus foreign or research-labeled products where origin and contents are often unknown.
Quick glossary
- FDA-approved drug - finished product that completed FDA approval for labeled uses.
- Compounded drug - custom-prepared medicine; not FDA-approved as a finished product.
- 503A - traditional compounding for an identified patient via state-licensed pharmacy or licensed physician.
- 503B - FDA-registered outsourcing facilities following CGMP; may compound with or without patient-specific Rx under 503B.
- CGMP - current good manufacturing practice (applies to 503B; 503A pathway drugs meeting all 503A conditions are exempt from CGMP under that section).
- Licensed U.S. channel - shorthand for 503A/503B frameworks-not a claim the finished compound is FDA-approved.
- "Research only" / "not for human consumption" - labels FDA has warned about when unapproved products are sold with human dosing instructions.
Why this comparison matters
"Compounding pharmacy," "503B," and "research-grade / imported" are not the same channels. 503A and 503B sit inside a known U.S. regulatory framework. FDA has warned about unapproved and research-labeled products. You can ask who prepared something, under which pathway, and what quality documentation exists.
A side-by-side snapshot (education only)
| Topic | 503A | 503B | Foreign / "research" / unapproved |
|---|---|---|---|
| Who compounds | State-licensed pharmacy or licensed physician (not an outsourcing facility) | FDA-registered outsourcing facility under licensed pharmacist supervision | Not a 503A/503B pathway; often unapproved products outside normal clinical channels |
| Patient-specific Rx | Generally a valid Rx for an identified patient | May or may not obtain identified-patient prescriptions | Often direct-to-consumer; FDA has warned about research-labeled products sold with human dosing |
| Traceability | Documented Rx; state-licensed pharmacy; ask about testing, COAs, sterile controls, BUD | FDA registration; CGMP; risk-based inspection; labeling "This is a compounded drug"; AE reporting | Frequently unknown origin/contents; little verifiable clinical pedigree |
| FDA registration as outsourcing facility | No | Yes | Not a substitute for 503A/503B |
| CGMP | Exempt if all 503A conditions met | Subject to CGMP | Not "CGMP-approved" because a site says research-grade |
| New-drug approval | Still not FDA-approved as a finished drug | Still not FDA-approved | Unapproved; no FDA safety/effectiveness/quality review |
| Accountability | State boards; pharmacist accountability; clinic-pharmacy relationship | FDA registration, CGMP, inspections, AE reporting | Often no clear U.S. pharmacy license or patient-specific Rx chain |
Sources: FDA FD&C Act compounding provisions; Outsourcing Facilities; 503A prescription guidance; FDA concerns with unapproved GLP-1 drugs.
What section 503A covers - and why patients still value this path
Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy (or federal facility) or a licensed physician when not registered as an outsourcing facility.
A licensed U.S. channel built around you
The heart of 503A is patient-specific care: clinician evaluation, a prescription that names you, and preparation under pharmacist or physician accountability-not a mystery vial.
What FDA's chart says about 503A conditions
Meeting all 503A conditions can exempt drugs from CGMP, adequate-directions labeling, and new-drug approval requirements. That is a known federal framework-not an FDA approval review of the finished compound. The product remains a compounded medicine and is not FDA-approved.
Patient-specific prescriptions under 503A
Compounding is for an identified individual patient based on a valid prescription (or limited anticipatory compounding when statutory conditions are met).
Questions you can ask about quality documentation (503A)
Ask about state licensure verification, testing practices, certificates of analysis, sterile process controls, beyond-use dating, and quality standards your clinician evaluates. With foreign research vials, patients often have no verifiable entity to ask.
What section 503B covers - registered facilities, CGMP, and FDA visibility
Section 503B outsourcing facilities compound sterile drugs, elect to register with FDA, and comply with 503B.
Why 503B is often described as a higher-visibility manufacturing-style path
- Must follow CGMP
- Risk-based FDA inspection
- Adverse-event reporting and product-information conditions
- May be exempt from approval and adequate-directions labeling-not from CGMP
- May or may not obtain identified-patient prescriptions
Labeling that tells you what it is
503B labels must include "This is a compounded drug."
What you can ask about a 503B source
Ask about FDA registration status, CGMP expectations, lot/quality documentation, adverse-event escalation, and whether labeling includes "This is a compounded drug." That does not make the product FDA-approved or "safer" than 503A.
Critical shared point: compounded != FDA-approved
FDA states compounded drugs are not FDA-approved-FDA does not verify safety, effectiveness, or quality before marketing. Under 503A or 503B they are still not brand-equivalent FDA-approved products. (FDA compounding Q&A)
What U.S. compounding gives you that foreign research channels usually don't
Traceability and a clinical chain
A licensed U.S. 503A/503B path gives you a clinician, a documented pathway, and entities you can identify. Research-labeled or foreign sales often do not.
Accountability and pedigree you can verify with your clinician
You can ask about pharmacy identity, registration, testing, and labeling-including "This is a compounded drug" on 503B containers.
What this does not mean
It does not mean compounded drugs are FDA-approved, risk-free, or appropriate for you.
Foreign, research-labeled, and other unapproved channels
FDA has warned consumers about unapproved products-including some sold as "research" with dosing for human use-and about quality concerns with certain foreign-sourced ingredients. Those channels are not substitutes for licensed U.S. compounding.
Import / foreign API quality concerns (FDA statements)
FDA has described quality and safety concerns with certain foreign active ingredients and unapproved finished products. Ask your clinician how they evaluate source and documentation.
Brief history context (secondary source)
Congressional Research Service summaries describe how federal compounding oversight evolved, including the 503A/503B framework after the DQSA. Secondary source only.
Practical questions patients can ask a clinician
- Is this 503A or 503B, and who is the licensed pharmacy or registered facility?
- Is there a prescription tied to me?
- What quality documentation does the clinic review?
- How is this different from a research-labeled or overseas product?
- Is this appropriate for my clinical plan-and what FDA-approved options exist?
FAQ
What is the difference between 503A and 503B?
503A is traditional patient-specific compounding via state-licensed pharmacy/physician. 503B is an FDA-registered outsourcing facility under CGMP that may compound with or without patient-specific prescriptions. Both produce compounded drugs that are not FDA-approved.
Are compounded drugs FDA-approved?
No. Compounded drugs are not FDA-approved.
If it's not FDA-approved, why do clinics still use compounding?
When clinically appropriate and lawful, compounding can serve individual patient needs inside a licensed U.S. framework. That is not a promise it is right for you.
Is a 503B product "safer" than a 503A product?
Different pathways, different frameworks-not a simple safer/better ranking. Neither is an FDA-approved finished drug.
What about products labeled "for research" or "not for human consumption"?
FDA has warned about unapproved products sold that way with human dosing instructions. That is not a licensed U.S. compounding channel.
Does Regen Therapy MD sell overseas research peptides?
Regen focuses on licensed clinical pathways discussed with a physician-not overseas research-peptide storefronts.
How do I talk with Regen Therapy MD?
Call (424) 349-6008 or use the site contact options for a free discovery call (non-clinical).
Talk with Regen Therapy MD
Questions about whether a licensed compounding pathway may be appropriate belong in a clinician conversation. Call (424) 349-6008.
Disclaimers (footer)
Education only. Not medical advice. Compounded drugs are not FDA-approved. Individual results vary. Services only where licensed.
.svg)
